1. The Evolving Role of Immunotherapy in NSCLC

3. This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States and data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

4. Currently Approved Checkpoint Inhibitors

5. Second-Line Clinical Trial Design Patient Selection by Histology in CheckMate Trials

6. Second-Line Clinical Trial Design Highlights of KEYNOTE-010 Design

7. Second-Line Clinical Trial Design Inclusion of IC PD-L1 Staining in OAK

8. First-Line Monotherapy Trial Design Unexpected Differences in Outcomes

9. First-Line Monotherapy Trial Design Assessment of CheckMate 026

10. TMB as a Biomarker Data From CheckMate 026

11. First-Line Combination Therapy Rationale

12. First-Line Combination Therapy KEYNOTE-021 Cohort G

13. First-Line Combination Therapy KEYNOTE-189

14. First-Line Combination Therapy IMpower150 Efficacy

15. First-Line Combination Therapy IMpower150 Safety

16. Challenges of Biomarker Development

17. Concerns With First-Line Combination Regimens

18. Impact of Crossover in First-Line Combination Trials

19. Durvalumab Post Chemoradiotherapy in the PACIFIC Trial

20. Factors That Can Influence Toxicity Rates

21. Choosing an Appropriate Immunotherapy

22. Concluding Remarks

23. Abbreviations

24. Abbreviations (cont)